Roche Pharmaceuticals is all set to address the unmet need in rheumatology by developing therapies that help patients achieve the ultimate goal of remission. This move is expected to benefit several patients who fail to respond effectively to the current treatments.
BERKELEY, Calif., Dec. 4, 2008 -- XOMA Ltd. , a leader in the discovery and development of antibody therapeutics, announced today that Steve Engle, Chairman and CEO of XOMA, is scheduled to present at the RBC Capital Markets Healthcare Conference.
POZEN Inc. (NASDAQ: POZN), today announced positive Phase 3 trial results for its PN 400 product candidate (enteric coated naproxen 500 mg and immediate release esomeprazole 20 mg) conducted by POZEN under an agreed Special Protocol Assessment with the FDA. Both the PN 400-301/302 studies achieved the primary endpoints.
Anika Therapeutics, Inc. (NASDAQ:ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, announced today that it has completed enrollment for its pivotal U.S. clinical trial for MONOVISC™.
